Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) 26% Dip In Price Shows Sentiment Is Matching Earnings

Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) shareholders won't be pleased to see that the share price has had a very rough month, dropping 26% and undoing the prior period's positive performance. Indeed, the recent drop has reduced its annual gain to a relatively sedate 2.1% over the last twelve months.

Even after such a large drop in price, given about half the companies in China have price-to-earnings ratios (or "P/E's") above 33x, you may still consider Cabio Biotech (Wuhan) as an attractive investment with its 25.4x P/E ratio. However, the P/E might be low for a reason and it requires further investigation to determine if it's justified.

With its earnings growth in positive territory compared to the declining earnings of most other companies, Cabio Biotech (Wuhan) has been doing quite well of late. One possibility is that the P/E is low because investors think the company's earnings are going to fall away like everyone else's soon. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.

View our latest analysis for Cabio Biotech (Wuhan)

Want the full picture on analyst estimates for the company? Then our free report on Cabio Biotech (Wuhan) will help you uncover what's on the horizon.

Does Growth Match The Low P/E?

There's an inherent assumption that a company should underperform the market for P/E ratios like Cabio Biotech (Wuhan)'s to be considered reasonable.

Taking a look back first, we see that the company grew earnings per share by an impressive 145% last year. However, this wasn't enough as the latest three year period has seen a very unpleasant 5.5% drop in EPS in aggregate. Therefore, it's fair to say the earnings growth recently has been undesirable for the company.

Turning to the outlook, the next year should generate growth of 22% as estimated by the four analysts watching the company. That's shaping up to be materially lower than the 38% growth forecast for the broader market.

With this information, we can see why Cabio Biotech (Wuhan) is trading at a P/E lower than the market. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.

What We Can Learn From Cabio Biotech (Wuhan)'s P/E?

The softening of Cabio Biotech (Wuhan)'s shares means its P/E is now sitting at a pretty low level. Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.

We've established that Cabio Biotech (Wuhan) maintains its low P/E on the weakness of its forecast growth being lower than the wider market, as expected. At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio. It's hard to see the share price rising strongly in the near future under these circumstances.

And what about other risks? Every company has them, and we've spotted 3 warning signs for Cabio Biotech (Wuhan) you should know about.

If these risks are making you reconsider your opinion on Cabio Biotech (Wuhan), explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.